Banking on iPSC- Is it Doable and is it Worthwhile
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
The discovery of induced pluripotent stem cells (iPSCs) and concurrent development of protocols for their cell-type specific differentiation have revolutionized studies of diseases and raised the possibility that personalized medicine may be achievable. Realizing the full potential of iPSC will require addressing the challenges inherent in obtaining appropriate cells for millions of individuals while meeting the regulatory requirements of delivering therapy and keeping costs affordable. Critical to making PSC based cell therapy widely accessible is determining which mode of cell collection, storage and distribution, will work. In this manuscript we suggest that moderate sized bank where a diverse set of lines carrying different combinations of commonly present HLA alleles are banked and differentiated cells are made available to matched recipients as need dictates may be a solution. We discuss the issues related to developing such a bank and how it could be constructed and propose a bank of selected HLA phenotypes from carefully screened healthy individuals as a solution to delivering personalized medicine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Human mesenchymal stem cells modulate allogeneic immune cell responses
Aggarwal, S., & Pittenger, M. F. (2005) · Blood · doi:10.1182/blood-2004-04-1559 · Cited by 4,511
Bjorkman, P. J., Saper, M. A., Samraoui, B., Bennett, W. S., Strominger, J. L., & Wiley, D. C. (1987) · Nature · doi:10.1038/329512a0 · Cited by 2,377
Transplantation of Embryonic Dopamine Neurons for Severe Parkinson's Disease
Freed, C. R., Greene, P. E., Breeze, R. E., Tsai, W.-Y., DuMouchel, W., Kao, R., Dillon, S., Winfield, H., Culver, S., Trojanowski, J. Q., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103083441002 · Cited by 2,366
What is immune privilege (not)?
Galea, I., Bechmann, I., & Perry, V. H. (2007) · Trends in Immunology · doi:10.1016/j.it.2006.11.004 · Cited by 768 · cited 1×
“Proponents of such allogeneic therapy model have argued that immune suppression may not be required in many cases such as when cells are only required for a short time period or when cells themselves are not immunogenic or when cells are transplanted into immune privileged sites [11–13].”
BackgroundTaylor, C. J., Peacock, S., Chaudhry, A. N., Bradley, J. A., & Bolton, E. M. (2012) · Cell stem cell · doi:10.1016/j.stem.2012.07.014 · Cited by 428
Guha, P., Morgan, J. W., Mostoslavsky, G., Rodrigues, N. P., & Boyd, A. S. (2013) · Cell stem cell · doi:10.1016/j.stem.2013.01.006 · Cited by 368
Pott Godoy, M. C., Tarelli, R., Ferrari, C. C., Sarchi, M. I., & Pitossi, F. J. (2008) · Brain · doi:10.1093/brain/awn101 · Cited by 335
Self-citationHLA engineering of human pluripotent stem cells
Riolobos, L., Hirata, R. K., Turtle, C. J., Wang, P.-R., Gornalusse, G. G., Zavajlevski, M., Riddell, S. R., & Russell, D. W. (2013) · Molecular Therapy · doi:10.1038/mt.2013.59 · Cited by 253
Toward the development of a global induced pluripotent stem cell library
Turner, M., Leslie, S., Martin, N. G., Peschanski, M., Rao, M., Taylor, C. J., Trounson, A., Turner, D., Yamanaka, S., & Wilmut, I. (2013) · Cell stem cell · doi:10.1016/j.stem.2013.08.003 · Cited by 245
Self-citationSTEIN-STREILEIN, J., & STREILEIN, J. W. (2002) · International Reviews of Immunology · doi:10.1080/08830180212066 · Cited by 218 · cited 1×
“Proponents of such allogeneic therapy model have argued that immune suppression may not be required in many cases such as when cells are only required for a short time period or when cells themselves are not immunogenic or when cells are transplanted into immune privileged sites [11–13].”
BackgroundNakajima, F., Tokunaga, K., & Nakatsuji, N. (2007) · Stem Cells · doi:10.1634/stemcells.2006-0566 · Cited by 168 · cited 1×
“Similar data with mismatched or allogeneic MSC suggest that MSC while not immune privileged are immunomodulatory and do not provoke a large rejection response and in many instances can tamp down a immune response [63–65].”
Result
Cited by
Genomic Instability of iPSCs: Challenges Towards Their Clinical Applications
Yoshihara, M., Hayashizaki, Y., & Murakawa, Y. (2017) · Stem Cell Reviews and Reports · doi:10.1007/s12015-016-9680-6 · Cited by 283
Baghbaderani, B. A., Tian, X., Neo, B. H., Burkall, A., Dimezzo, T., Sierra, G., Zeng, X., Warren, K., Kovarcik, D. P., Fellner, T., et al. (2015) · Stem Cell Reports · doi:10.1016/j.stemcr.2015.08.015 · Cited by 212
“In the HLA haplobank model that has been proposed (Turner et al., 2013; Solomon et al., 2015), the same line may be used for multiple individuals in addition to multiple indications.”
BackgroundMethodSelf-citationOlgasi, C., Cucci, A., & Follenzi, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176215 · Cited by 100
Parrotta, E. I., Lucchino, V., Scaramuzzino, L., Scalise, S., & Cuda, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124354 · Cited by 88
“To overcome this issue, Solomon and colleagues have proposed the establishment of a biobank containing several iPSC lines reprogrammed from healthy donors carrying different combinations of human leukocyte antigen (HLA) alleles in order to provide a shared and economic starting point from which iPSC-derived differenti…”
BackgroundAzuma, K., & Yamanaka, S. (2016) · Regenerative Therapy · doi:10.1016/j.reth.2016.01.009 · Cited by 63
Metadata
- Authors
- Solomon, S., Pitossi, F., & Rao, M. S.
- Venue
- Stem Cell Reviews and Reports
- Published
- 2014-12-17
- Volume
- 11
- Issue
- 1
- Pages
- 1-10
- ISSN
- 1550-8943 (ISSN-L)
- 1558-6804
- OpenAlex
- W2054436996
- Cited by
- 86
- References
- 11
- FWCI
- 3.89
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.